Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 10;79(18):1849-1857.
doi: 10.1016/j.jacc.2022.02.046.

Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison

Michelle D Kelsey  1 , Adam J Nelson  2 , Jennifer B Green  3 , Christopher B Granger  4 , Eric D Peterson  5 , Darren K McGuire  5 , Neha J Pagidipati  4
Affiliations
Review

Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison

Michelle D Kelsey et al. J Am Coll Cardiol. .

Abstract

Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies.

Keywords: guidelines; prevention; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Kelsey is supported by National Institute of Health (NIH) training grant 5T32HL069749-18. Dr Granger has received research grants from AKROS, Apple, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Duke Clinical Research Institute, the U.S. Food and Drug Administration, GlaxoSmithKline, Janssen Pharmaceutical Products, L.P., Medtronic Foundation, Novartis Pharmaceuticals, and Pfizer; and has received consulting fees from Abbvie, Abiomed, Anthos Therapeutic, LLC, Bayer Corporation, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, CeleCor Therapeutics, Correvio, Espero BioPharma, Janssen Pharmaceutica Products, L.P., Medscape, LLC, Medtronic Inc, Merck, Novo Nordisk, Novartis Pharmaceutical Company, Pfizer, Phillips, Rhoshan Pharmaceuticals, and Roche Diagnostics. Dr Green has received research support from Boehringer Ingelheim/Lilly, Sanofi/Lexicon, Merck, and Roche; and has received consulting fees from Boehringer Ingelheim/Lilly Alliance, NovoNordisk, AstraZeneca, Pfizer, and Hawthorne Effect/Omada. Dr Peterson has received research support from Amgen Inc, Janssen Pharmaceutical Products, Bristol Myers Squibb, and Esperion; and has received consulting fees from Janssen Pharmaceutical Products, Boehringer Ingelheim, Novartis, and Cerner. Dr McGuire has received honoraria for clinical trial leadership from Boehringer Ingelheim, Sanofi Aventis, Merck & Co, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA, Lexicon, and CSL Behring; and has received honoraria for consultancy from Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, Metavant, Sanofi Aventis, and Afimmune. Dr Pagidipati has received research grants from Amgen, Inc., AstraZeneca, Baseline Study LLC, Boehringer Ingelheim, Duke Clinical Research Institute, Eli Lilly & Company, Novartis Pharmaceuticals, Novo Nordisk Pharmaceutical Company, Regeneron Pharmaceuticals, Inc, Sanofi-S.A., and Verily Sciences Research Company; and has received consulting fees from AstraZeneca, Boehringer Ingelheim, Esperion Therapeutics, Eli Lilly & Company, and Novo Nordisk Pharmaceutical Company. Dr Nelson has reported that he has no relationships relevant to the contents of this paper to disclose.

Publication types

MeSH terms

Substances